Zenas BioPharma (ZBIO) Stock Price, News & Analysis

Company Overview

Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for patients with serious autoimmune diseases. The company’s research is centered on medicines designed to modulate the immune system while potentially avoiding the broad immune-cell depletion associated with some existing treatments.

Zenas’ lead product candidate is obexelimab, an investigational monoclonal antibody designed to bind CD19 and FcγRIIb receptors on B cells. Through this mechanism, obexelimab is intended to inhibit B-cell activity without eliminating the cells. The company is evaluating the therapy in immune-mediated diseases, including IgG4-related disease and systemic lupus erythematosus.

Zenas BioPharma was established to advance therapies for autoimmune and other immune-mediated conditions and conducts clinical development activities through studies involving patients in multiple geographic regions. The company is headquartered in Waltham, Massachusetts, and its shares began trading on the Nasdaq under the symbol ZBIO in 2024.

Key Stats

• Today's Range: $26.78 to $28.70
• 50-Day Range: $26.76 to $33.77
• 52-Week Range: $13.50 to $44.60
• Volume: 92,487 shs
• Average Volume: 817,942 shs
• Market Capitalization: $1.87 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $46.71
• Consensus Rating: Moderate Buy

Zenas BioPharma Stock Analysis - MarketRank™

Zenas BioPharma scored higher than 49% of companies evaluated by MarketBeat, and ranked 513th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Zenas BioPharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Zenas BioPharma has a consensus price target of $46.71, representing about 68.5% upside from its current price of $27.73.

Amount of Analyst Coverage

Zenas BioPharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Zenas BioPharma are expected to grow in the coming year, from ($5.81) to ($4.87) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zenas BioPharma is -3.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zenas BioPharma is -3.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Zenas BioPharma has a P/B Ratio of 6.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

23.35% of the float of Zenas BioPharma has been sold short.

Short Interest Ratio / Days to Cover

Zenas BioPharma has a short interest ratio ("days to cover") of 22.43, which indicates bearish sentiment.

Change versus previous month

Short interest in Zenas BioPharma has recently increased by 1.44%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zenas BioPharma does not currently pay a dividend.

Dividend Growth

Zenas BioPharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.39

News Sentiment

Zenas BioPharma has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Zenas BioPharma this week, compared to 5 articles on an average week.

Search Interest

Only 1 people have searched for ZBIO on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

MarketBeat Follows

2 people have added Zenas BioPharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Zenas BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.00% of the stock of Zenas BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Zenas BioPharma has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/07/2026
• Investor update: 10/27/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ZBIO
• Previous Symbol: NASDAQ:ZBIO
• CIK: 1953926
• Web: zenasbio.com
• Phone: (857) 271-2954
• Fax: N/A
• Employees: 167
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Zenas BioPharma: $46.71
• High Price Target: $55.00
• Low Price Target: $32.00
• Potential Upside/Downside: +63.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($8.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$377.74 million
• Net Margins: N/A
• Pretax Margin: -48,416.40%
• Return on Equity: -122.45%
• Return on Assets: -58.04%

Debt

• Debt-to-Equity Ratio: 1.57
• Current Ratio: 9.93
• Quick Ratio: 9.93

Sales & Book Value

• Annual Sales: $10 million
• Price / Sales: 185.94
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.51 per share
• Price / Book: 6.33

Miscellaneous

• Outstanding Shares: 65,180,000
• Free Float: 50,838,000
• Market Cap: $1.86 billion
• Optionable: N/A
• Beta: -0.90